Business Wire--August 17, 2004

Common side effects of HIV-1 infection and HAART include metabolic changes, mitochondrial toxicity, and oxidative stress characterized by loss of lean muscle mass, decreased immune function, and diminished quality of life. The objective of this pilot study was to assess the efficacy of Resurgex on these problems. A key ingredient in Resurgex is an orally effective form of Superoxide dismutase, which is the body's primary antioxidant defense enzyme, (SOD)/Gliadin (Defenzyme(TM)).

According to lead investigator Dr. H. Rahman, M.D., "Resurgex was shown to be beneficial to the patients' quality of life, and dramatically improving their key metabolic and immunologic functions."

The study found improvements in a number of key quality of life indicators in symptomatic patients, including:

-- 96 percent of patients reported they were less tired;

-- 91 percent reported increased energy levels;

-- 91 percent said they required less sleep during the day, while 82 percent said they slept better at night;

-- 86 percent said they had a demonstrated improvement in their daily activities;

-- 86 percent reported a demonstrated improvement in their social life, and

-- 82 percent of subjects reported an improvement in their depression.

"For years, the role of nutritional supplements in the treatment of disease and the subsequent effects on quality of life were ignored or discounted by members of the medical community," stated Carl Germano, RD, CNS, CDN and senior vice president; product development and research, Millennium Biotechnologies.

"A growing body of clinical research, like that recently done at St. Mary's is altering this perspective by demonstrating the critical role key nutrients can play in advancing the health and well being of people dealing with immuno-compromised conditions."

The Resurgex study also showed a statistically significant improvement in Karnofsky Performance Status (KPS) scores, which are commonly used to classify functional impairment. KPS is used to compare the effectiveness of different therapies and to assess the prognosis in individual patients. The lower the KPS score, the worse the survival for most serious illnesses. In this case, over 90 percent of patients who began the trial with low KPS scores raised those scores and were able to perform normal activity with only minor symptoms after just 24 weeks.

The study also showed that compliant patients who took Resurgex had increased improvement in a number of key metabolic parameters that relate to quality of life, including:

-- 75 percent of patients with elevated lactic acid demonstrated a reduction in lactic acid of at least 15 percent (with an average of 31 percent);

-- More than half of patients (53 percent) with depressed CD4 counts had an increase of at least 15 percent in CD4 count, and

-- Over one third (33.3 percent) of patients with depressed hemoglobin experienced improvement of 15 percent.

Resurgex has received AIDS Drug Assistance Program (ADAP) Approval in New York and Medicaid approval in New York, New Jersey, Pennsylvania, Connecticut and Nevada. The product has been available in the medical market for over three years, with over 500,000 doses administered orally with no significant adverse effects reported. Resurgex can also be administered via feeding tube.

About KCSA Worldwide

KCSA Worldwide is a leading public and investor relations firm with practice areas in public relations, investor relations, corporate and marketing communications, and design and graphics. KCSA is the U.S. partner of European Communication Partners, a network of public relations firms in EEC countries and Canada, and the U.S. member of IR Asia-Pacific Ltd., the world's first network of independent investor relations consultancies. The firm has strategic alliances in Australia, Israel, Russia and South America.

About Millennium Biotechnologies

Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies, Group Inc. is a pioneer in the research and development and marketing of medical nutritional supplements. Millennium owns the exclusive rights to RESURGEX(R) and RESURGEX Plus(TM), multiple action nutritional formulas containing the critically important, orally effective form of (SOD)/Gliadin (Defenzyme(TM))) and several other essential nutritional components. Millennium products are designed to assist in increasing energy, maintaining lean muscle, reducing oxidative stress and supporting immune function in patients with HIV/AIDS, Hepatitis C, cancer or other immuno-compromised conditions as an adjunct to their medical care. Additional information about Millennium Biotechnologies, Inc., is available at www.milbiotech.com.

This news release contains forward-looking statements that are based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions on the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

CONTACT: KCSA Worldwide

Anne Donohoe, 212-896-1261

adonohoe@kcsa.com

Katie Bestenlehner, 212-896-1269

kbest@kcsa.com

SOURCE: Millennium Biotechnologies

040817
BW040811

Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .